Development of a live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a subcutaneous administration of a recombinant canarypoxvirus expressing FELV genes.

×

Error message

  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 53 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice: Trying to access array offset on value of type null in bootstrap_pager() (line 95 of /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
Development of a live vaccine against feline leukemia. Experiment outside containment (clinical trial) for the study of the safety of a subcutaneous administration of a recombinant canarypoxvirus expressing FELV genes.
EU record number: 
B/BE/97/VW9
Company / Sponsor: 
Merial
Treated organism: 
cats
Indication category: 
vaccination against feline leukemia virus (FELV)
Genetic modification: 
env and gag genes of the type A virus of feline leukemia (FELV)
Method of transfer of nucleic acid of interest: 
Canarypoxvirus (ALVAC clone)
Route of administration: 
subcutaneous
Locations in Belgium: 
Merksem, Heverlee, Mechelen, Deurne, Izegem, Haine St Pierre, Ternat, Overijse, Liège
Nr of subjects: 
400
Foreseen duration: 
6 months
Type of procedure: 
Deliberate release only

Information related to the decision procedure